Shai Mulinari
1 – 20 of 86
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2023
-
Mark
Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy
(
- Contribution to journal › Article
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
-
Mark
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
2023) In Big Data and Society(
- Contribution to journal › Article
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
(
- Contribution to journal › Article
-
Mark
Authors’ reply to Fell
(
- Contribution to journal › Letter
- 2022
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
(
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
-
Mark
De unga gör helt rätt när de stämmer staten
2022) In Aftonbladet(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
-
Mark
“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
2022) In BioSocieties(
- Contribution to journal › Article
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
(
- Contribution to journal › Article
-
Mark
The making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Sociologisk forskning om covid-19-pandemin : En introduktion
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article